DAYTON, OH – Orthomod LLC, a medical device company driving material innovations for orthopedics and spine surgery, announces FDA clearance of its new MOD-C™ cervical intervertebral implant family for the treatment of degenerative disc disease of the cervical spine from C2-T1. This milestone represents the clearance of a novel, permanent biomaterial composite for use in orthopedic and spine surgery.
CAMP (calcium-acrylic modified polymer) is a unique composite of an acrylic polymer and synthetic beta-tricalcium phosphate/hydroxyapatite (B-TCP/HA). The product of extensive development efforts by biomaterials experts, the CAMP platform introduces an important new material option for structural orthopedic implants. Designed with a broad range of potential applications in spine, reconstructive orthopedics, dentistry, sports medicine, and oncology, the CAMP platform promises to address a significant share of the $60 billion orthopedic implant market.